Considering that PDLIM2 expression is affected in a larger range of cell types in infectious diseases compared to lung cancer, nanoPDLIM2 or other PDLIM2-targeted therapies may offer even better efficacy and safety for patients with infectious diseases. This evidence concerns the gene PDLIM2 and infectious disease.